Last reviewed · How we verify
HSK39297 200mgQD
At a glance
| Generic name | HSK39297 200mgQD |
|---|---|
| Sponsor | Haisco Pharmaceutical Group Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN (PHASE3)
- Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN (PHASE2)
- Phase II Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients with Primary IgAN (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HSK39297 200mgQD CI brief — competitive landscape report
- HSK39297 200mgQD updates RSS · CI watch RSS
- Haisco Pharmaceutical Group Co., Ltd. portfolio CI